 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- || THV-01 / TheraVectys
Trial completion: Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (clinicaltrials.gov) - Apr 19, 2019
P1/2, N=38, Completed, Sponsor: Theravectys S.A.
Active, not recruiting --> Completed
- THV-01 / TheraVectys
Trial primary completion date: Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=38, Active, not recruiting, Sponsor: Theravectys S.A.
Active, not recruiting --> Completed Trial primary completion date: Nov 2014 --> Nov 2015
- | THV-01 / TheraVectys
New P1/2 trial: Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (clinicaltrials.gov) - Feb 2, 2014
P1/2, N=36, Active, not recruiting, Sponsor: Theravectys S.A.
- | THV-01 / TheraVectys
Enrollment closed: Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (clinicaltrials.gov) - Feb 2, 2014
P1/2, N=36, Active, not recruiting, Sponsor: Theravectys S.A.
Trial primary completion date: Nov 2014 --> Nov 2015 Not yet recruiting --> Active, not recruiting